Financial Performance - The company's operating revenue for Q3 2023 was ¥34,326,150.54, a decrease of 26.38% compared to the same period last year, and a cumulative revenue of ¥104,759,853.14, down 33.02% year-on-year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥9,459,873.30, an increase of 681.72% year-on-year, while the cumulative net profit was ¥486,718.30, a decrease of 9.99%[5]. - The basic and diluted earnings per share for Q3 2023 were both ¥0.0304, reflecting a significant increase of 684.62% compared to the same period last year[5]. - Total operating revenue for Q3 2023 was ¥104,759,853.14, a decrease of 32.98% compared to ¥156,404,576.30 in the same period last year[22]. - Net profit for Q3 2023 was ¥4,709,236.40, a decline of 42.56% compared to ¥8,159,911.17 in Q3 2022[24]. - The company reported a basic and diluted earnings per share of ¥0.0016 for Q3 2023, compared to ¥0.0017 in the previous year[24]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥542,187,740.19, a decrease of 1.97% from the end of the previous year[5]. - Total assets as of Q3 2023 amounted to ¥542,187,740.19, a slight decrease from ¥553,064,727.36 at the end of the previous period[20]. - Total liabilities decreased to ¥457,594,303.92 from ¥473,180,527.49, reflecting a reduction of 3.43%[20]. - The company's total liabilities decreased by 39.56% in short-term borrowings, amounting to ¥38,126,871.29[10]. - The company's non-current assets totaled ¥122,739,211.11, down from ¥136,828,754.20, indicating a decrease of 10.29%[20]. Cash Flow - The company’s cash flow from operating activities decreased by 84.32% to ¥20,424,564.32 year-to-date[5]. - Operating cash flow for the current period is ¥20,424,564.32, a decrease of 84.3% compared to ¥130,252,235.42 in the previous period[26]. - Total cash inflow from operating activities is ¥155,278,948.10, down 50% from ¥310,456,290.99 year-on-year[26]. - The company’s cash flow from operating activities is impacted by a significant reduction in cash received from sales, which decreased to ¥141,635,801.14 from ¥172,792,521.72[26]. - Cash flow from investment activities shows a net inflow of ¥12,500,503.93, compared to a net outflow of ¥20,892,052.90 in the previous period[27]. - Cash inflow from investment activities totals ¥424,144,822.76, significantly up from ¥138,063,913.25 in the previous period[27]. - Cash outflow from financing activities is ¥60,813,352.83, down from ¥138,579,523.05 in the previous period[27]. - The company’s cash and cash equivalents at the end of the period stand at ¥218,230,076.45, compared to ¥188,825,485.09 at the end of the previous period[27]. - The company received ¥28,000,000.00 from borrowings, down 56.9% from ¥65,040,000.00 in the previous period[27]. - The company paid ¥53,036,250.00 in debt repayments, an increase of 51.5% compared to ¥35,000,000.00 in the previous period[27]. Inventory and Investments - The company’s inventory increased by 61.58% to ¥7,272,355.80, primarily due to the addition of raw materials and inventory goods[10]. - Accounts receivable increased to 162,608,054.37 RMB from 158,759,054.35 RMB at the start of the year[18]. - Inventory rose to 7,272,355.80 RMB, up from 4,500,707.82 RMB at the beginning of the year[18]. - The company’s long-term equity investments slightly decreased to 5,479,883.06 RMB from 5,484,304.54 RMB[18]. - The company reported a significant increase in investment income of 656.15%, amounting to ¥787,244.74, compared to a loss of ¥141,553.29 in the previous year[11]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,982[13]. - The largest shareholder, Hunan Caixin Industrial Fund Management Co., holds 25.58% of shares, totaling 79,701,655 shares[13]. - The company has no preferred shareholders as of the reporting date[15]. Future Plans and Developments - The company plans to raise up to 276 million RMB through a private placement of A-shares to its controlling shareholder[15]. - The company plans to focus on market expansion and new product development to drive future growth[20]. - The company has ongoing research and development expenses of ¥6,938,971.61, slightly up from ¥6,895,486.58 year-on-year, indicating continued investment in innovation[22]. - The company has not disclosed any new product or technology developments in this report[15]. Tax and Other Income - The company reported a significant reduction in income tax expenses, down 76.05% to ¥1,160,896.78, due to decreased income tax from subsidiaries[11]. - The company’s other income decreased by 65.80% to ¥1,396,589.58, mainly due to a reduction in government subsidies received[11]. Audit Status - The company has not undergone an audit for the third quarter report[28].
南华生物(000504) - 2023 Q3 - 季度财报